Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

Daniel A Barocas1, Peter E Clark

  • 1Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2765, USA.

Current Opinion in Oncology
|April 9, 2008
PubMed
Summary
This summary is machine-generated.

Recent advancements in bladder cancer care focus on improved detection via cystoscopy and fluorescent light, alongside new urinary markers. Management strategies for superficial and invasive bladder cancer are evolving, with ongoing research into novel treatments and bladder preservation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

The Journal of urology·2026
Same author

Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI.

The Journal of urology·2026
Same author

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).

The Journal of urology·2026
Same author

Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

European urology·2026
Same author

Predicting Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Model Development and Evaluation in an International Cohort Study.

Clinical genitourinary cancer·2026
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Urology
  • Oncology

Background:

  • Bladder cancer diagnosis and management are critical areas in urologic oncology.
  • Continuous research aims to improve patient outcomes and quality of life.

Purpose of the Study:

  • To review recent advancements in bladder cancer diagnosis and management.
  • Emphasis on studies and developments from the past year.

Main Methods:

  • Review of current literature on bladder cancer diagnosis and treatment.
  • Focus on cystoscopy, urinary markers, surgical interventions, and chemotherapy.

Main Results:

  • Cystoscopy with fluorescent light enhances bladder cancer detection.
  • Transurethral resection and intravesical bacillus Calmette-Guerin are key for superficial disease.

Related Experiment Videos

  • Radical cystectomy remains standard for muscle-invasive disease, with ongoing research in minimally invasive approaches and bladder preservation.
  • Chemotherapy regimens like methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine and cisplatin (GC) are common, with efforts to develop cisplatin-ineligible regimens.

    • Conclusions:

    • Progress in bladder cancer diagnosis and management is encouraging.
    • Further research is essential to enhance patient care and outcomes.